FREE SHIPPING

on all orders of $59 or more

$8 OFF your purchase of $100 or more!
Use coupon code WEDNESDAY in checkout.

The Sarcomere and Skeletal Muscle Disease

, by
The Sarcomere and Skeletal Muscle Disease by Laing, Nigel G., Ph.D., 9780387848464
Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
  • ISBN: 9780387848464 | 0387848460
  • Cover: Hardcover
  • Copyright: 3/1/2009
  • Rent Textbook

    (Recommended)

    $231.74
     
    Term
    Due
    Price
  • Buy New Textbook

    In Stock Usually Ships in 24 Hours

    $237.64
Sarcomeric Disease: Advances and Some Unanswered QuestionsThe gene, and its protein product, in a serious inherited muscle disease was first identified in the case of Duchenne muscular dystrophy some twenty years ago. Dystrophin turned out to be a sarcolemmal protein. This was somewhat of a surprise because many had harboured the view up until then that most muscle diseases, if not all, might be due to defects in the sarcomere itself. After all this was the site of muscle contraction. However many other muscular dystrophies have subsequently been shown to be due to defects in various other sarcolemma-associated proteins. 1The structure of the sarcomere itself has been studied and known for many years. 2 But only in more recent times has the role of its structural and contractile proteins been detailed in specific muscle diseases. The cytoskeleton is held together by filamentous proteins, such as a-actinin and desmin, and the microtubular protein tubulin. Other proteins are nebulin and telethonin and the elastic element titin. Finally there are the contractile proteins troponin, tropomyosin, actin and myosin. Here experts in the field describe a variety of diseases associated with defects in these sarcomeric proteins often first suspected because of a pronounced accumulation of the relevant protein in the muscle tissue.Recently a few, relatively rare dystrophies themselves have also been shown to be associated with defects in sarcomeric proteins, for example, myotilin in LGMD1A, telethonin in LGMD2G, and titin in LGMD2J. The latter is of particular interest in the present context. Whereas homozygous mutation of the titin gene result in the autosomal recessive, severe, early onset 2J form of limb-girdle muscular dystrophy, heterozygosity for the same and other dominant mutations results in a mild, late onset form of distal (tibial) myopathy. 3,4 Furthermore myotilin mutations have now been demonstrated in myofibrillar myopathy, or desmin-related myopathy, as well as in LGMD1A. 5These observations and several other examples in the text raise fundamental questions: how do we explain the very different clinical phenotypes which can result from different mutations in the same gene, and occasionally in different members of the same family with the same mutation? This problem is not unique to the sarcomeric diseases. It is also well exemplified in the case of mutations of the LMNA gene resulting in multiple laminopathies, defects in nuclear membrane proteins, a problem which has been recognised for some time. 6Further detailed analysis of specific mutations in these disorders may provide some answers. But it is also possible that studying associations with single nucleotide polymorphisms or copy number variants 7-10 may be helpful though so far most of this research has centred more on commoner multifactorial conditions. These seem to be unexplored territories in regard to genetic forms of muscle disease. Furthermore acute quadriplegic myopathy, due to a preferential loss of myosin and myosin-associated thick filament proteins, is acquired and not genetic.It is also perhaps possible that certain common pathogens could affect disease presentation via their interaction with, for example, actin filaments and the induced filament rearrangements. 11 But again this is a field which has so far not been explored.The results of the studies presented in this volume now pave the way for much future research into the pathogenesis of this group of fascinating conditions, leading one day to their treatment. References:1. Winder SJ, ed. Molecular Mechanisms of Muscular Dystrophies. Austin: Landes Bioscience, 2006.2. Hanson J, Huxley HE. Structural basis of cross st

You might also enjoy...



Please wait while the item is added to your bag...